CClinicalTrials.gg
CompletedNCT03006328GEMUpdated Apr 27, 2023Results posted

The GEM (Goals for Eating and Moving) Study

An interventional study of GEM and Enhanced Usual Care in Weight Gain and Obesity, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
489
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Study summary

The GEM intervention leverages the patient-centered medical home model by using the GEM tool to provide individually tailored, patient-centered care, promote standardized weight management counseling by health coaches and primary team members, coordinate care between teams and other weight management service providers/programs (e.g., dietitians, health educators, DPP), and provide feedback to the provider and primary care team about patients' weight management-related goals, progress, and care.

Read the detailed description

To establish the efficacy of the GEM intervention, investigators will conduct a cluster randomized controlled 12-month intervention of 19 primary care teams at two urban healthcare systems with Medical Home models of care to compare the GEM intervention (intervention arm) with Enhanced Usual Care (educational materials; control arm).

The specific aims of this study are:

  • Test the impact of the GEM intervention on weight change, and clinical and behavioral outcomes.
  • Identify predictors of weight loss in the GEM intervention arm related to: a) goal-setting processes and b) intervention components
  • Determine the impact of the GEM intervention on obesity-related counseling practices and attitudes in primary care providers.
02

Conditions studied

  • Weight Gain
  • Obesity

Browse trials for

Keywords

  • weight gain
  • weight loss
03

In context

Weight Gain

405 studies on the registry are indexed under Weight Gain; 52 are open to participants now.

This study's enrollment of 489 is above the median of 83 across 324 interventional studies indexed under Weight Gain.

Browse Weight Gain studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Between the ages of 18-69 years of age,
  • Body mass index of ≥30kg/m2 OR
  • Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
  • Hypertension
  • High Cholesterol
  • Sleep Apnea
  • Osteoarthritis
  • Metabolic Syndrome
  • Prediabetes
  • Under primary care team care with at least one prior visit with their provider in the past 24 months
  • Access to a telephone, and ability to travel for in-person evaluations at baseline, 6, 12, and 24 months

Exclusion criteria

Exclusion Criteria:

  • Patients who do not speak English or Spanish,
  • Have active psychosis or other cognitive issues,
  • Psychoactive substance use
  • Diabetes
  • Taking prescription weight-loss medication
  • Health condition that may prohibit the patient from walking or physical activity such as chest tightness, a heart condition, or severe arthritis
  • Participated in MOVE!, DPP, or another intensive weight management program (>3 sessions) in the past year,
  • Have a history of bariatric surgery,
  • Are pregnant, or become pregnant during the intervention period,
  • Metastatic cancer in the last 6 months, current chemotherapy or cancer treatment,
  • Have a provider who states they should not participate,
  • Patients who do not want to lose weight
  • Have self-reported inability to read at 5th grade level.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
489 participants (actual)

Study arms

  • Experimental
    Participants with Obesity + GEM

    Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will be assigned to GEM Tool and a health coach.

    Behavioral: GEM

  • Active comparator
    Participants with Obesity + Enhanced Usual Care

    Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will receive receive non-tailored weight management handouts by health coaches.

    Behavioral: Enhanced Usual Care

Interventions

  • BehavioralGEM

    Online program designed to support health coach and primary care team counseling. It assesses current behaviors, barriers, and facilitators to weight loss via a 16-item questionnaire, provides tailored advice, and guides patients to set weight loss (5-10%), diet, and physical activity (PA) goals. After completing the tool, participants will meet with a Health Coach. Participants will receive 12 telephone coaching calls by a health coach over 12 months.

  • BehavioralEnhanced Usual Care

    Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.

06

What researchers measure

Primary outcomes

  1. Change in Weight From Baseline

    Time frame: Baseline, Month 12

  2. Change in Waist Circumference From Baseline

    Time frame: Baseline, Month 12

  3. Change in Systolic Blood Pressure (SBP) From Baseline

    Time frame: Baseline, Month 12

  4. Change in Diastolic Blood Pressure (DBP) From Baseline

    Time frame: Baseline, Month 12

07

Results

Posted Apr 27, 2023

Participant flow

Participant flow — Overall Study
MilestoneParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Started220269
Completed220269
Not completed00

Outcome measures

PrimaryChange in Weight From Baseline
Time frame:
Baseline, Month 12
Reported as:
Mean · kilograms
Change in Weight From Baseline
kilogramsParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Change in Weight From Baseline-1.4 ± 0.8-0.8 ± 0.9
PrimaryChange in Waist Circumference From Baseline
Time frame:
Baseline, Month 12
Reported as:
Mean · centimeters
Change in Waist Circumference From Baseline
centimetersParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Change in Waist Circumference From Baseline-1.3 ± 0.5-0.6 ± 0.6
PrimaryChange in Systolic Blood Pressure (SBP) From Baseline
Time frame:
Baseline, Month 12
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure (SBP) From Baseline
mmHgParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Change in Systolic Blood Pressure (SBP) From Baseline1.8 ± 1.73.2 ± 1.7
PrimaryChange in Diastolic Blood Pressure (DBP) From Baseline
Time frame:
Baseline, Month 12
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure (DBP) From Baseline
mmHgParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Change in Diastolic Blood Pressure (DBP) From Baseline1.6 ± 1.43.2 ± 1.5

Adverse events

Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Obesity + GEM1/220 (0.5%)53/220 (24.1%)36/220 (16.4%)
Participants With Obesity + Enhanced Usual Care3/269 (1.1%)81/269 (30.1%)43/269 (16%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Foot fractureInjury, poisoning and procedural complications2/2205/269
Wrist/hand injuryInjury, poisoning and procedural complications0/2205/269
Abdominal SurgerySurgical and medical procedures4/2200/269
Chest PainCardiac disorders4/2201/269
Gallbladder DiseaseGastrointestinal disorders0/2204/269
Back painMusculoskeletal and connective tissue disorders3/2204/269
DepressionPsychiatric disorders3/2201/269
Motor vehicle accidentInjury, poisoning and procedural complications3/2203/269
Kidney pain/stonesRenal and urinary disorders2/2203/269
Knee painMusculoskeletal and connective tissue disorders1/2203/269
Most frequent other events
Showing 10 of 43
Most frequent other events
EventParticipants With Obesity + GEMParticipants With Obesity + Enhanced Usual Care
Chest painsCardiac disorders5/2200/269
Shoulder pain/injuryMusculoskeletal and connective tissue disorders3/2205/269
Back painMusculoskeletal and connective tissue disorders4/2201/269
COVID-19 infectionInfections and infestations0/2204/269
Wrist/hand injuryInjury, poisoning and procedural complications2/2203/269
MigrainesNervous system disorders0/2203/269
DepressionPsychiatric disorders2/2200/269
Acute muscle spasmMusculoskeletal and connective tissue disorders2/2200/269
DyspneaRespiratory, thoracic and mediastinal disorders2/2201/269
FallInjury, poisoning and procedural complications2/2201/269

Baseline characteristics

Age, Continuous
Age, Continuous(years)Participants With Obesity + GEMParticipants With Obesity + Enhanced Usual CareTotal
Mean49.2 ± 12.150.2 ± 11.649.8 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Participants With Obesity + GEMParticipants With Obesity + Enhanced Usual CareTotal
Female116157273
Male104112216
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants With Obesity + GEMParticipants With Obesity + Enhanced Usual CareTotal
Hispanic or Latino99100199
Not Hispanic or Latino116166282
Unknown or Not Reported538
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants With Obesity + GEMParticipants With Obesity + Enhanced Usual CareTotal
American Indian or Alaska Native011
Asian224
Native Hawaiian or Other Pacific Islander112
Black or African American96142238
White354176
More than one race61016
Unknown or Not Reported8072152
Region of Enrollment
Region of Enrollment(participants)Participants With Obesity + GEMParticipants With Obesity + Enhanced Usual CareTotal
United States220269489
08

Study locations

1 site
  • New York University Medical Center Institutional Review Boards
    New York, New York 10016, United States
09

References and documents

Publications

  • Merriwether EN, Wittleder S, Cho G, Bogan E, Thomas R, Bostwick N, Wang B, Ravenell J, Jay M. Racial and weight discrimination associations with pain intensity and pain interference in an ethnically diverse sample of adults with obesity: a baseline analysis of the clustered randomized-controlled clinical trial the goals for eating and moving (GEM) study. BMC Public Health. 2021 Dec 2;21(1):2201. doi: 10.1186/s12889-021-12199-1. PubMed 34856961 ↗
  • Wittleder S, Ajenikoko A, Bouwman D, Fang Y, McKee MD, Meissner P, Orstad SL, Rehm CD, Sherman SE, Smith S, Sweat V, Velastegui L, Wylie-Rosett J, Jay M. Protocol for a cluster-randomized controlled trial of a technology-assisted health coaching intervention for weight management in primary care: The GEM (goals for eating and moving) study. Contemp Clin Trials. 2019 Aug;83:37-45. doi: 10.1016/j.cct.2019.06.005. Epub 2019 Jun 20. PubMed 31229622 ↗
  • Viglione C, Bouwman D, Rahman N, Fang Y, Beasley JM, Sherman S, Pi-Sunyer X, Wylie-Rosett J, Tenner C, Jay M. A technology-assisted health coaching intervention vs. enhanced usual care for Primary Care-Based Obesity Treatment: a randomized controlled trial. BMC Obes. 2019 Feb 4;6:4. doi: 10.1186/s40608-018-0226-0. eCollection 2019. PubMed 30766686 ↗

Study documents

  • Protocol and statistical analysis plan · Dec 15, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03006328
Lead sponsor
NYU Langone Health
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
Nov 20, 2017
Primary completion
May 20, 2020
Completion
Feb 22, 2022
Results posted
Apr 27, 2023
Last update
Apr 27, 2023

Study contacts

Melanie Jay, MD
principal investigator · NYU School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion